MedTrace Logo

Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use

NCT05445180 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2026-05-22

No results posted yet for this study

Summary

Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.

Conditions

  • Psychotic Disorders
  • Cannabis Use Disorder
  • Cannabis Dependence
  • Cannabis Use
  • Schizophrenia; Psychosis
  • Cognitive Dysfunction
  • Memory Impairment
  • Neuroimaging

Interventions

BEHAVIORAL

Contingency management

Contingency management will be used to encourage abstinence

Sponsors & Collaborators

  • Douglas Mental Health University Institute

    lead OTHER

Principal Investigators

  • Rachel Rabin, Ph. D. · Douglas Mental Health University Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-21
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05445180 on ClinicalTrials.gov